Street Calls of the Week
Investing.com - Citizens maintained its Market Outperform rating and $8.00 price target on ProQR Therapeutics N.V. (NASDAQ:PRQR) following an investor dinner in New York. The company’s stock has shown remarkable strength with an 80.5% return over the past six months, according to InvestingPro data.
The research firm hosted the dinner earlier this week, where ProQR Therapeutics management met with investors to discuss company developments.
According to Citizens, investors at the event showed particular interest in the upcoming Phase 1 readout for AX-0810 and what the results might mean for the drug candidate’s development path.
The $8.00 price target remains unchanged, with Citizens basing its valuation on a risk-adjusted, sum-of-the-parts analysis of the company’s pipeline.
ProQR Therapeutics is a biopharmaceutical company focused on developing RNA therapies for genetic diseases. The company maintains a strong financial position with more cash than debt and a healthy current ratio of 3.76. Investors should note that the next earnings release is scheduled for November 5th. InvestingPro subscribers have access to 8 additional ProTips and comprehensive financial analysis for deeper insights into PRQR’s performance.
In other recent news, ProQR Therapeutics N.V. has received authorization to commence a Phase 1 clinical trial for its RNA editing therapy, AX-0810. This approval comes from the Central Committee on Research Involving Human Subjects under the European Medicines Agency’s centralized review process. The trial will involve healthy volunteers in the Netherlands, marking a significant step for the company’s development pipeline. Additionally, Citizens has reiterated its Market Outperform rating for ProQR, maintaining a price target of $8.00. Analyst Jonathan Wolleben from Citizens based this rating on a risk-adjusted, sum-of-the-parts analysis of ProQR’s RNA technology. These developments highlight ProQR’s ongoing progress in clinical trials and its favorable standing among analysts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.